Sarepta Therapeutics, INC 10-Q quarterly reports

Sarepta Therapeutics reported a substantial decrease in product revenue for Q2 2026, primarily driven by lower ELEVIDYS sales, while collaboration revenue saw an increase.

Sarepta Therapeutics announces Q1 2026 financial results, with significant revenue shifts and ongoing R&D focus.

Sarepta Therapeutics reports a significant net loss in Q3 2025, driven by ELEVIDYS shipment suspensions, a strategic restructuring, and a failed confirmatory trial for two PMO products.

Sarepta Therapeutics reported a net loss for the first half of 2025, driven by significant R&D investments and legal challenges, despite strong ELEVIDYS revenue growth.

Sarepta Therapeutics' Q1 2025 results showcase significant revenue growth driven by ELEVIDYS and the initiation of a major collaboration with Arrowhead Pharmaceuticals, alongside increased R&D spending.

Sarepta Therapeutics' Q3 2024 results show a significant increase in revenue, primarily driven by sales of ELEVIDYS, and a return to profitability.

Sarepta Therapeutics' Q2 2024 results show a significant increase in revenue driven by the launch of ELEVIDYS, despite a decrease in collaboration revenue.

Sarepta Therapeutics' first quarter 2024 results show a significant increase in revenue driven by the launch of ELEVIDYS, alongside updates on clinical programs and financial positions.